secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0000950170-23-039048
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q2 total revenues $49M (+157% YoY); Tyvaso DPI royalties $19M (+63% QoQ)
--------------------------------------------------------------------------------

- Tyvaso DPI royalties $19M in Q2, up 63% from Q1, driven by strong patient demand.
- Afrezza net revenue $13.5M, up 27% YoY due to higher demand and price.
- GAAP income from operations $2M; non-GAAP income from operations $8M.
- Total revenues H1 2023 $89.2M, +189% vs H1 2022.
- Cash and investments $146.6M as of June 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000095017023039048/0000950170-23-039048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000095017023039048/mnkd-20230807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer